Regulation of food preference using GLP-1 agonists

Abstract

GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono-and di-saccharides together constitute a large proportion of the total amount of carbohydrates.

1 . A method for reducing intake of food by a subject, wherein said food has a glycemic index above 60%, said method comprising administering to said subject an effective amount of a GLP-1 agonist.  
     
     
         2 . A method of reducing intake of food by a subject, wherein said food has a glycemic index above 40%, and wherein more than 30% of the total energy in said food stems from fat, said method comprising administering to said subject an effective amount of a GLP-1 agonist.  
     
     
         3 . A method for reducing intake of food by a subject, wherein mono-and di-saccharides in said food together constitute more than 25% of the total amount of carbohydrate in said food, said method comprising administering to said subject an effective amount of a GLP-1 agonist.  
     
     
         4 . The method according to  claim 3 , wherein more than 30% of the total energy in said food stems from fat.  
     
     
         5 . A method of increasing intake of food by a subject, wherein said food has a glycemic index below 60%, said method comprising administering to said subject an effective amount of a GLP-1 agonist.  
     
     
         6 . A method of increasing intake of food by a subject, wherein said food has a glycemic index below 40%, and wherein less than 30% of the total energy in said food stems from fat, said method comprising administering to said subject an effective amount of a GLP-1 agonist.  
     
     
         7 . A method of increasing intake of food by a subject wherein mono-and di-saccharides in said food together constitute less than 25% of the total carbohydrate content in said food, said method comprising administering to said subject an effective amount of a GLP-1 agonist.  
     
     
         8 . The method according to  claim 7 , wherein less than 30% of the total energy in said food stems from fat.  
     
     
         9 . A method for treating a disease or disorder in a subject where the disease or disorder is selected from the group consisting of binge eating, bulimia nervosa and craving for food, the method comprising administering to said subject an amount of a GLP-1 agonist effective to treat said disease or disorder.  
     
     
         10 . A method of treating obesity in a subject, wherein said obesity is caused by binge eating disorder, bulimia nervosa, craving for food or snacking, the method comprising administering to said subject an effective amount of a GLP-1 agonist.  
     
     
         11 . A method according to  claim 1 , wherein said GLP-1 agonist is administered in connection with a meal.  
     
     
         12 . A method according to  claim 1 , wherein said subject is a human, a pet animal or a zoo animal.  
     
     
         13 . A method according to  claim 12 , wherein said subject is a human.  
     
     
         14 . A kit comprising: (a) a GLP-1 agonist which reduces the intake of food with a high glycemic index or food wherein mono-and di-saccharides together constitute a large proportion of the total amount of carbohydrates in a container; and (b) a notice associated with said container in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by said agency of said GLP-1 compound for human or veterinary administration to reduce intake of food with a high glycemic index or food wherein mono- and di-saccharides together constitute a large proportion of the total amount of carbohydrates.  
     
     
         15 . The method according to  claim 1 , wherein said GLP-1 agonist is a GLP-1(7-36)-amide or GLP-1(7-37).  
     
     
         16 . The method according to  claim 1 , wherein said GLP-1 agonist is an analogue or a derivative of an analogue of GLP-1(7-36)-amide or GLP-1(7-37).  
     
     
         17 . The method according to  claim 16 , wherein said derivative is Arg 34 , Lys 26 (N ε -(γ-Glu(N ε -hexadecanoyl)))-GLP-1(7-37).  
     
     
         18 . The method according to  claim 1 , wherein said GLP-1 agonist is exendin-4, an exendin-4 analogue or a derivative of said exendin-4 or exendin-4 analogue.  
     
     
         19 . The method according to  claim 18 , wherein said GLP-1 agonist is exendin-4.